| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 19.56 | 9.78 | 8.68 | 8.68 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,693.82 | 2,637.16 | 2,134.04 | 2,108.9 |
Net Worth | 2,713.38 | 2,646.94 | 2,142.72 | 2,117.58 |
Minority Interest | ||||
Debt | 131.89 | 97.9 | 144.35 | 289.58 |
Deferred Tax Liability Net | 113.87 | 102.9 | 107.76 | 104.68 |
Total Liabilities | 2,959.14 | 2,847.74 | 2,394.83 | 2,511.84 |
Fixed Assets | 935.68 | 848.48 | 814.57 | 835.36 |
Intangible Assets | ||||
Investments | 1,222.77 | 1,235.9 | 246.45 | 243.92 |
Deferred Tax Asset Net | 98.1 | 64.14 | 82.89 | 78.5 |
Networking Capital | 691.71 | 694.72 | 1,246.46 | 1,349.23 |
Inventories | 175.03 | 148.58 | 111.92 | 94.5 |
Inventory Days | ||||
Sundry Debtors | 222.66 | 176.77 | 143.82 | 111.9 |
Debtor Days | ||||
Other Current Assets | 461.53 | 524.07 | 1,097.41 | 1,228.15 |
Sundry Creditors | -110.13 | -72.35 | -61.31 | -39.66 |
Creditor Days | ||||
Other Current Liabilities | -57.38 | -82.35 | -45.38 | -45.66 |
Cash | 10.88 | 4.5 | 4.46 | 4.83 |
Total Assets | 2,959.14 | 2,847.74 | 2,394.83 | 2,511.84 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
